modelJ04AB03
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Rifamycin | |
| ATC code: | J04AB03 | route: | oral |
| compartments: | 1 | |
| dosage: | 400 | mg |
| volume of distribution: | 17 | L |
| clearance: | 6 | L/h |
| other parameters in model implementation | ||
Rifamycin is an antibiotic belonging to the rifamycin group, used primarily for the treatment of tuberculosis and other bacterial infections caused by susceptible strains. It exerts its antibacterial action by inhibiting DNA-dependent RNA polymerase in susceptible organisms. Rifamycin preparations are approved and used clinically, with formulations for oral, intravenous, or local (e.g., intestinal) administration.
Pharmacokinetics
Pharmacokinetic parameters after a single oral dose of rifamycin SV in healthy adult volunteers.
References
Hoy, SM (2019). Rifamycin SV MMX. Clinical drug investigation 39(7) 691–697. DOI:10.1007/s40261-019-00808-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31172447
Scarpignato, C, & Pelosini, I (2005). Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 51 Suppl 1 36–66. DOI:10.1159/000081990 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15855748
Zheng, C, et al., & Gao, F (2017). Clinical and pharmacological hallmarks of rifapentine's use in diabetes patients with active and latent tuberculosis: do we know enough?. Drug design, development and therapy 11 2957–2968. DOI:10.2147/DDDT.S146506 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29066867
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)